HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management
Abstract Human papillomavirus (HPV)-positive (HPV+) oropharyngeal squamous cell
carcinoma (OPSCC) has one of the most rapidly increasing incidences of any cancer in high …
carcinoma (OPSCC) has one of the most rapidly increasing incidences of any cancer in high …
Tumour-intrinsic resistance to immune checkpoint blockade
Abstract 'Immune checkpoint blockade'for cancer describes the use of therapeutic antibodies
that disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour …
that disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour …
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
F Skoulidis, JV Heymach - Nature Reviews Cancer, 2019 - nature.com
The impressive clinical activity of small-molecule receptor tyrosine kinase inhibitors for
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …
mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy
T Tian, X Li, J Zhang - International journal of molecular sciences, 2019 - mdpi.com
The mammalian or mechanistic target of rapamycin (mTOR) pathway plays a crucial role in
regulation of cell survival, metabolism, growth and protein synthesis in response to upstream …
regulation of cell survival, metabolism, growth and protein synthesis in response to upstream …
The molecular landscape of head and neck cancer
CR Leemans, PJF Snijders, RH Brakenhoff - Nature Reviews Cancer, 2018 - nature.com
Head and neck squamous cell carcinomas (HNSCCs) arise in the mucosal linings of the
upper aerodigestive tract and are unexpectedly heterogeneous in nature. Classical risk …
upper aerodigestive tract and are unexpectedly heterogeneous in nature. Classical risk …
Impact of oncogenic pathways on evasion of antitumour immune responses
S Spranger, TF Gajewski - Nature Reviews Cancer, 2018 - nature.com
Immunotherapeutic interventions are showing effectiveness across a wide range of cancer
types, but only a subset of patients shows clinical response to therapy. Responsiveness to …
types, but only a subset of patients shows clinical response to therapy. Responsiveness to …
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label …
TY Seiwert, B Burtness, R Mehra, J Weiss… - The lancet …, 2016 - thelancet.com
Background Patients with recurrent or metastatic squamous cell carcinoma of the head and
neck have few treatment options. We aimed to assess the safety, tolerability, and antitumour …
neck have few treatment options. We aimed to assess the safety, tolerability, and antitumour …
Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase …
Purpose Treatment with pembrolizumab, an anti–programmed death-1 antibody, at 10
mg/kg administered once every 2 weeks, displayed durable antitumor activity in …
mg/kg administered once every 2 weeks, displayed durable antitumor activity in …
[HTML][HTML] The head and neck cancer immune landscape and its immunotherapeutic implications
Recent clinical trials have demonstrated a clear survival advantage in advanced head and
neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint blockade …
neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint blockade …
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments
Head and neck squamous cell carcinoma (HNSCC) comprises a heterogeneous group of
tumors that arise from the squamous epithelium of the oral cavity, oropharynx, larynx and …
tumors that arise from the squamous epithelium of the oral cavity, oropharynx, larynx and …